A5062827464- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Radiopharmaceutical Chemistry and Applications
- Ubiquitin and proteasome pathways
- Medical Imaging Techniques and Applications
- Hormonal and reproductive studies
- Antifungal resistance and susceptibility
- Cancer Research and Treatments
- Receptor Mechanisms and Signaling
- Mycobacterium research and diagnosis
- Cancer-related gene regulation
- Cytomegalovirus and herpesvirus research
- Pharmacogenetics and Drug Metabolism
- Estrogen and related hormone effects
- Legionella and Acanthamoeba research
University of California, San Francisco
2022-2024
Chemoenzymatic techniques have been applied extensively to pharmaceutical development, most effectively when routine synthetic methods fail. The regioselective and stereoselective construction of structurally complex glycans is an elegant application this approach that seldom positron emission tomography (PET) tracers. We sought a method dimerize 2-deoxy-[18F]-fluoro-d-glucose ([18F]FDG), the common tracer used in clinical imaging, form [18F]-labeled disaccharides for detecting...
Abstract Purpose: With the improvement in overall survival with 177Lu-PSMA 617, radioligand therapy (RLT) is now a viable option for patients metastatic castration-resistant prostate cancer (mCRPC). However, responses are variable, part due to low PSMA expression 30% of patients. Herein, we evaluated whether cell surface protein CUB domain-containing 1 (CDCP1) can be exploited treat mCRPC RLT, including PSMA-low subsets. Experimental Design: CDCP1 levels were using RNA sequencing from 119...
Despite recent approvals for checkpoint inhibitors and antibody-drug conjugates targeting NECTIN4 or TROP2, metastatic bladder cancer remains incurable new treatment strategies are urgently needed. CUB domain-containing protein 1 (CDCP1) is a cell surface promising drug target many cancers. This study aimed to determine whether CDCP1 expressed in can be targeted with radiolabeled antibodies.CDCP1 expression was evaluated four datasets (n = 1,047 biopsies). A tissue microarray of primary...
Understanding how the host immune system engages complex pathogens is essential to developing therapeutic strategies overcome their virulence. While granzymes are well understood trigger apoptosis in infected cells or bacteria, less known about mobilizes individual granzyme species vivo combat diverse pathogens. Toward goal of studying function directly vivo, we previously developed a new class radiopharmaceuticals termed "restricted interaction peptides (RIPs)" that detect biochemically...
Demonstrating target engagement in vivo is an important milestone drug development, both to establish on target, tissue interactions but also identify potentially undesirable off binding. The glucocorticoid receptor (GR) a long-studied yet vexing that has recently re-emerged as potential druggable driver of many solid tumor types including breast and prostate cancer, several antagonists are currently early phase clinical trials. Since GR ubiquitously expressed normal tissues, understanding...
Supplementary Figure from CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease
Supplementary Figure from CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease
Supplementary Figure from CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease
Supplementary Figure from CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease
<div>AbstractPurpose:<p>With the improvement in overall survival with 177Lu-PSMA 617, radioligand therapy (RLT) is now a viable option for patients metastatic castration-resistant prostate cancer (mCRPC). However, responses are variable, part due to low PSMA expression 30% of patients. Herein, we evaluated whether cell surface protein CUB domain-containing 1 (CDCP1) can be exploited treat mCRPC RLT, including PSMA-low subsets.</p>Experimental Design:<p>CDCP1 levels...
Supplementary Figure from CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease
Supplementary Figure from CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease
Supplementary Figure from CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease
Supplementary Figure from CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease
<div>AbstractPurpose:<p>With the improvement in overall survival with 177Lu-PSMA 617, radioligand therapy (RLT) is now a viable option for patients metastatic castration-resistant prostate cancer (mCRPC). However, responses are variable, part due to low PSMA expression 30% of patients. Herein, we evaluated whether cell surface protein CUB domain-containing 1 (CDCP1) can be exploited treat mCRPC RLT, including PSMA-low subsets.</p>Experimental Design:<p>CDCP1 levels...
Supplementary Figure from CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease
Supplementary Figure from CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease
Supplementary Figure from CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease
Supplementary Figure from CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease
Supplementary Figure from CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease
Supplementary Figure from CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease
Supplementary Figure from CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease